ENDRA Life Sciences Awarded Three Additional U.S. Patents for Cloud-enabled Connectivity of Medical Devices
August 02 2022 - 8:00AM
Business Wire
TAEUS® now protected by 53 patents issued
globally, including 31 in the U.S.
New U.S. patents expand potential licensing
opportunities in data management
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of
imaging technologies and Thermo Acoustic Enhanced UltraSound
(TAEUS®), announces that the United States Patent & Trademark
Office has issued three new patents to ENDRA including U.S. Patent
No. 11379343 (the ‘343 patent), U.S. Patent No. 11392479 (the ‘479
patent) and U.S. Patent No. 11405470 (the ‘470 patent). All three
patents are titled “Methods and Systems for Exchange of Equipment
Performance Data.”
“We are pleased to be issued these three patents that, along
with a previously issued U.S. patent, provide broad protection for
our proprietary method to transfer equipment performance data to
cloud-based services. In addition to protecting data management for
our TAEUS system, these patents provide licensing opportunities
with other equipment manufacturers,” stated ENDRA's Chairman and
Chief Executive Officer Francois Michelon. "We continue to enhance
our intellectual property portfolio to protect our technology in
priority global markets. Our portfolio currently includes 53
patents issued globally, of which 31 patents are issued in the
U.S.”
These three newly issued patents are part of a patent family
that protects ENDRA’s proprietary method and system for acquiring,
analyzing and sharing data in the cloud. The ‘343 and ‘479 patents
protect ENDRA's data sharing capabilities that are specific to the
medical imaging industry. The ‘470 patent builds upon the company’s
U.S. Patent No. 11314617 (the ‘617 patent). Both the ‘470 and ‘617
patents have claims that are narrower than the ‘343 and ‘479
patents and apply to industries outside of medical imaging. The
‘470 patent broadens ENDRA’s coverage from devices “not having
internet connectivity” (as described in the ‘617 patent) to devices
that are “communicatively insulated.”
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced
UltraSound (TAEUS®), a ground-breaking technology being developed
to visualize tissue like MRI, but at 1/50th the cost and at the
point of patient care. TAEUS® is designed to work in concert with
over 500,000 ultrasound systems in use globally today. TAEUS® is
initially focused on the measurement of fat in the liver as a means
to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and
inflammation (NASH), chronic liver conditions that affect over one
billion people globally, and for which there are no practical
diagnostic tools. Beyond the liver, ENDRA is exploring several
other clinical applications of TAEUS®, including visualization of
tissue temperature during energy-based surgical procedures. For
more information, please visit www.endrainc.com.
Forward-Looking Statements
All statements in this press release that are not based on
historical fact are "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements, which
are based on certain assumptions and describe our future plans,
strategies and expectations, can generally be identified by the use
of terms such as “approximate,” "anticipate," “attempt,” "believe,"
"could," "estimate," "expect," “forecast,” “future,” "goal,"
“hope,” "intend," "may," "plan," “possible,” “potential,”
“project,” "seek," "should," "will," “would,” or other comparable
terms (including the negative of any of the foregoing), although
some forward-looking statements are expressed differently. Examples
of forward-looking statements for ENDRA include, among others:
estimates of the timing of future events and anticipated results of
our development efforts, including the timing for receipt of
required regulatory approvals and product launches; future
financial position and projected costs and revenue; expectations
concerning ENDRA's business strategy; ENDRA’s ability to find and
maintain development partners; market acceptance of ENDRA’s
technology and the amount and nature of competition in its
industry; and ENDRA’s ability to protect its intellectual property.
Forward-looking statements involve inherent risks and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements as a result of various factors
including, among others: the ability to raise additional capital in
order to continue as a going concern; the ability to obtain
regulatory approvals necessary to sell ENDRA medical devices in
certain markets in a timely manner, or at all; the ability to
develop a commercially feasible technology and its dependence on
third parties to design and manufacture its products; the impact of
COVID-19 on ENDRA’s business plans; the ability to find and
maintain development partners; market acceptance of ENDRA’s
technology and the amount and nature of competition in its
industry; ENDRA’s ability to protect its intellectual property; and
the other risks and uncertainties described in the Risk Factors and
Management’s Discussion and Analysis of Financial Condition and
Results of Operations sections of the Company’s most recent Annual
Report on Form 10-K and in subsequent Quarterly Reports on Form
10-Q filed with the Securities and Exchange Commission. You should
not rely upon forward-looking statements as predictions of future
events. The forward-looking statements made in this press release
speak only as of the date of issuance, and ENDRA assumes no
obligation to update any such forward-looking statements to reflect
actual results or changes in expectations, except as otherwise
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220801005644/en/
Irina Pestrikova Senior Director, Finance investors@endrainc.com
www.endrainc.com
Investor Relations: Yvonne Briggs LHA Investor Relations (310)
691-7100 YBriggs@lhai.com
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Apr 2023 to Apr 2024